VXRT vs. BCRX

In the year-to-date period, VXRT achieves a -24.51% return, which is significantly lower than BCRX's 37.90% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Vaxart, Inc. (VXRT) and BioCryst Pharmaceuticals, Inc. (BCRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VXRT Sharpe Ratio is -0.48, which is lower than the BCRX Sharpe Ratio of 1.18. The chart below compares the historical Sharpe Ratios of VXRT and BCRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither VXRT nor BCRX has paid dividends to shareholders.

The maximum VXRT drawdown since its inception was -98.69%, roughly equal to the maximum BCRX drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for VXRT and BCRX. For additional features, visit the drawdowns tool.

Vaxart, Inc. (VXRT) has a higher volatility of 31.08% compared to BioCryst Pharmaceuticals, Inc. (BCRX) at 24.20%. This indicates that VXRT's price experiences larger fluctuations and is considered to be riskier than BCRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Vaxart, Inc. and BioCryst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.